Here are four things to know.
1. Through the deal, Actelion will transform its research and development operations and early-stage clinical development assets into a new biotech company listed in Switzerland, according to the report.
2. J&J will own 16 percent of the new biotech, with the right to acquire an additional 16 percent. Actelion shareholders will also receive shares of the new company.
3. Actelion CEO Jean-Paul Clozel and Actelion chairman Jean-Pierre Garnier will take over their respective roles at the new company.
4. The deal, unanimously approved by both companies’ boards, is expected to close by the end of the second quarter of 2017, pending shareholder and regulatory approval.
More articles on supply chain:
3 ways to improve supplier relationships
4 top priorities for supply chain leaders in 2017
Viewpoint: 3 regulatory changes that could lower drug costs
At the Becker's 11th Annual IT + Revenue Cycle Conference: The Future of AI & Digital Health, taking place September 14–17 in Chicago, healthcare executives and digital leaders from across the country will come together to explore how AI, interoperability, cybersecurity, and revenue cycle innovation are transforming care delivery, strengthening financial performance, and driving the next era of digital health. Apply for complimentary registration now.
